China's second PARP inhibitor - zele, approved for market!

Recently, the State Drug Administration approved the first class innovative drug toluenesulfonate nilapaly capsule (trade name: zele) of zaiding Pharmaceutical (Shanghai) Co., Ltd to be put on the market through the priority review and approval procedure, which is used for the maintenance treatment of platinum sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in adult patients after complete or partial remission of platinum containing chemotherapy Cure Nilaparil is an inhibitor of PARP-1 and PARP-2 The marketing of nilaparil toluenesulfonate capsule will provide a new choice for Chinese patients The State Food and drug administration requires drug marketing license holders to continue to complete the clinical research currently being carried out according to the plan after the drug is marketed Zele ® is the first approved product of zaiding pharmaceutical in mainland China and the second approved PARP inhibitor in China Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.